NeuroSense Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons

NeuroSense Therapeutics (NASDAQ:NRSN) has reported positive initial results from its Phase 2 RoAD clinical trial of PrimeC for Alzheimer's disease. The study, conducted in collaboration with NeuroKaire, demonstrated that PrimeC enhanced neuroplasticity in patient-derived neurons while showing no treatment-related toxicity.

Using NeuroKaire's proprietary technology, which converts patient blood samples into brain cells, researchers observed improvements in brain-cell connectivity and health. The ongoing Phase 2 trial is a randomized, double-blind, placebo-controlled study evaluating PrimeC in mild-to-moderate Alzheimer's patients over 12 months.

https://www.stocktitan.net/news/NRSN/neuro-sense-s-drug-candidate-shows-early-signals-of-benefit-in-e2sr3ri4o7fd.html